Cargando…

DDRE-07. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS

Brain metastases are refractory to therapies that otherwise control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the unique brain microenvironment contributes to this therapy resistance. Nutrient availability can vary across tissues, therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraro, Gino, Ali, Ahmed, Luengo, Alba, Kodack, David, Deik, Amy, Abbott, Keene, Bezwada, Divya, Blanc, Landry, Prideaux, Brendan, Jin, Xin, Possada, Jessica, Chen, Jiang, Chin, Christopher, Amoozgar, Zohreh, Ferreira, Raphael, Chen, Ivy, Naxerova, Kamila, Ng, Christopher, Westermark, Anna, Duquette, Mark, Roberge, Sylvie, Lyssiotis, Costas, Duda, Dan, Golub, Todd, Cantley, Lewis, Asara, John, Davidson, Shawn, Fukumura, Dai, Dartois, Véronique, Clish, Clary, Heiden, Matthew Vander, Jain, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992317/
http://dx.doi.org/10.1093/noajnl/vdab024.029
Descripción
Sumario:Brain metastases are refractory to therapies that otherwise control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the unique brain microenvironment contributes to this therapy resistance. Nutrient availability can vary across tissues, therefore metabolic adaptations required for breast cancer growth in the brain microenvironment may also introduce liabilities that can be exploited for therapy. Here, we assessed how metabolism differs between breast tumors growing in the brain versus extracranial sites and found that fatty acid synthesis is elevated in breast tumors growing in the brain. We determine that this phenotype is an adaptation to decreased lipid availability in the brain relative to other tissues, which results in a site-specific dependency on fatty acid synthesis for breast tumors growing at this site. Genetic or pharmacological inhibition of fatty acid synthase (FASN) reduces HER2+ breast tumor growth in the brain, demonstrating that differences in nutrient availability across metastatic sites can result in targetable metabolic dependencies.